ISMRM20 Sunrise: Body MRS: Cancer

Sunrise Session

Body MRS: Cancer

Back to Program-at-a-Glance

Session Topic: Educational Q&A: MRS Sunrise

Session Sub-Topic: Body MRS: Cancer

Sunrise Session

ORGANIZERS: Wolfgang Bogner, Malgorzata Marjanska

Wednesday Parallel 2 Live Q&A

Wednesday, 12 August 2020, 13:45 - 14:30 UTC

Moderators: Patrick Bolan & Savannah Partridge

Skill Level: Basic to Advanced

Session Number: S-Tu-05

Overview
This course will cover methodological and clinical topics from basic to advanced applications of body MR spectroscopy in oncology, exemplified by applications of MRS in breast and prostate cancers for diagnosis and treatment monitoring.

Target Audience
Researchers and clinical users of MR spectroscopy interested in applying MRS in diagnosis and treatment of breast lesions, prostate tumors, or primary neoplasms and metastasis in other body regions outside the brain.

Educational Objectives
As a result of attending this course, participants should be able to:
- Summarize the MRS and MRSI methods that can be used in a clinical (research) setting to investigate cancer;
- Recognize the potential added value of body MRS to other MRI and molecular imaging techniques; and
- List current clinical and research applications of body MR spectroscopy.

		MRS of the Breast Paola Clauser Watch the Video MRS has been used for many years but has not yet become a part of the routine in breast MRI. A specific expertise and a narrow collaboration between different specialists is necessary to perform MRS. There is currently no standard regarding how MRS of the breast should be performed, and different approaches are used. Several metabolites can be analyzed with MRS. Currently choline is by far the most investigated. MRS could be applied for several indication in the breast, the most clinically relevant one being the characterization of indeterminate breast lesions, the evaluation of tumor aggressiveness and response to chemotherapy.
		MRS of the Prostate John Kurhanewicz Watch the Video Increasing evidence points to prostate cancer being a disease linked to abnormal metabolism, and in this lecture metabolic shifts associated with the presence and progression of prostate cancer and it’s response/resistance to treatment will be described. The quantitative pre-clinical MRS based metabolic and correlative biology studies used to identify biomarkers and the use of these biomarkers in in vivo ¹H and HP ¹³C magnetic resonance spectroscopic imaging studies of patients will be discussed. The need for studies comparing MRSI approaches with current imaging modalities such as multiparametric ¹H MRI for localized and PET for metastatic cancer will also be discussed.